相关实验视频
Updated: Jul 18, 2025

06:48
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
35.2K
血清蛋白酶抑制剂减少前列腺癌,乳腺癌和卵巢癌的转移
Amiram Sananes1, Itay Cohen1, Irit Allon2
1Avram and Stella Goldstein-Goren Department of Biotechnology Engineering and the National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Molecular oncology
|August 23, 2023
概括
针对美索素和卡利克林6 (KLK6) 蛋白酶的新疗法对晚期前列腺癌,乳腺癌和卵巢癌具有前途. 这些基于粉样β蛋白前体库尼茨蛋白酶抑制剂域 (APPI) 突变的新型药物有效向瘤并抑制转移.
科学领域:
- 在瘤学瘤学.
- 生物化学 生物化学
- 药物发现 药物发现 药物发现
背景情况:
- 目前的癌症疗法主要针对初级瘤,忽视了转移过程.
- 前列腺癌,乳腺癌和卵巢癌的转移与中素和卡利克林6 (KLK6) 的活性增加有关.
- 梅索西和KLK6被确定为抗转移干预措施的关键目标.
研究的目的:
- 开发针对中素和KLK6治疗晚期转移性癌症的新型治疗剂.
- 评估基于APPI的突变体作为抗转移疗法的疗效和特性.
- 探索这些药物的癌症成像潜力.
主要方法:
- 开发人类粉样β蛋白前体昆尼茨蛋白酶抑制剂域 (APPI) 的工程突变.
- 针对前列腺癌和乳腺癌的APPI-3M,以及针对卵巢癌的APPI-4M的指定.
- 在 ортотоп模型中进行临床前测试,以评估瘤积累,治疗疗效和药物动力学特性.
主要成果:
- APPI-3M和APPI-4M突变体在瘤中显示出显著的积累.
- 在先进转移性癌症的临床前模型中证明了治疗疗效.
- 在体内表现出很长的保留时间,高亲和力和有利的药理动力学.
结论:
- 工程APPI突变体代表了转移性前列腺癌,乳腺癌和卵巢癌的有希望的新疗法.
- 这些药物具有适用于治疗干预和诊断成像的特征.
- 开发的疗法具有良好的安全性,并且可以在规模上制造.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
MicroRNAs
21.4K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.4K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K

